Trends in Late Stage Licensing
Executive SummaryWhat type of pharmaceutical companies are the most aggressive licensors of late-stage products? In Vivo examines late-stage deals by type of licensor over the past three years to get an idea.
You may also be interested in...
The US Senate’s vote to approve legislation underpinning the US-Mexico-Canada trade agreement has been welcomed by the country’s off-patent industry.
By merging to create Viatris, Mylan and Pfizer’s Upjohn unit intend to occupy a space between generics players and big pharma by offering a broad array of affordable products all around the world.